Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Co-trimoxazole is a fixed-dose antibacterial combination of **sulfamethoxazole**, a sulfonamide that inhibits bacterial dihydropteroate synthase, and **trimethoprim**, an inhibitor of bacterial dihydrofolate reductase. The sequential inhibition of microbial folate synthesis produces synergistic antimicrobial activity. It is administered orally or intravenously and is used for susceptible bacterial infections and for treatment or prophylaxis of *Pneumocystis jirovecii* pneumonia. A randomized Khon Kaen University study is evaluating 12 versus 20 weeks of oral eradication therapy for relapse prevention in culture-confirmed melioidosis. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/018374s029lbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethoxazole + trimethoprim (GSK).